HDAX Therapeutics is a biopharmaceutical and biotechnology startup that was founded in 2021. The company operates within the biopharma, biotechnology, and pharmaceutical industries. Known for its groundbreaking advancements in the field, HDAX Therapeutics received a significant Seed Round investment on September 28, 2022. The investment was made by FACIT, further solidifying the company's position as a promising venture in the biotech sector. With this recent investment, HDAX Therapeutics is poised for rapid growth and substantial contributions to the healthcare and biopharmaceutical industries.
No recent news or press coverage available for HDAX Therapeutics.